Increasing hydroxyurea dose helps young sickle cell patients avoid hospitalization
Автор: St. Jude Children's Research Hospital
Загружено: 2017-11-14
Просмотров: 15370
Описание:
Sickle cell disease is the most common inherited blood disorder in the U.S. and affects about 100,000 Americans. St. Jude researchers pioneered use of the drug hydroxyurea more than 20 years ago to treat sickle cell disease in young people. The drug works by increasing production of fetal hemoglobin, which functions normally in sickle cell patients. In a recent study, scientists report that maximizing the dose of hydroxyurea increased levels of fetal hemoglobin and reduced the odds of hospitalizations for young sickle cell anemia patients.
Read the press release: http://ow.ly/2eQe30gtaZt
Read the paper: http://ow.ly/ayQi30gteCz
Jeremie Estepp, M.D.: https://www.stjude.org/estepp
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
